Glycemic Variability of Tirzepatide vs. Insulin Degludec in People with Type 2 Diabetes Using Continuous Glucose Monitoring (SURPASS-3 CGM)

被引：0
|
作者：
Bergenstal, Richard M.
Bartee, Amy
Zeytinoglu, Meltem
Bray, Ross
Allen, Sheryl
Brown, Katelyn
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-728-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
728-P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] EFFECT OF TIRZEPATIDE VERSUS INSULIN DEGLUDEC ON GLYCEMIC CONTROL CAPTURED WITH CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH TYPE 2 DIABETES (SURPASS-3 CGM)
    Battelino, T.
    Bergenstal, R.
    Rodriguez, A.
    Lando, L. Fernandez
    Bray, R.
    Tong, Z.
    Brown, K.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A37 - A38
  • [2] The Effect of Tirzepatide vs. Insulin Degludec on Post-meal Glucose Control in Patients with Type 2 Diabetes (SURPASS-3 CGM)
    Battelino, Tadej
    Johnson, Jennal
    Katz, Michelle
    Bray, Ross
    Xue, Jie
    Brown, Katelyn
    DIABETES, 2023, 72
  • [3] Effect of tirzepatide versus insulin degludec on glycaemic control captured with continuous glucose monitoring in patients with type 2 diabetes (SURPASS-3 CGM)
    Battelino, T.
    Bergenstal, R.
    Rodriguez, A.
    Lando, L. Fernandez
    Bray, R.
    Tong, Z.
    Brown, K.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 244 - 244
  • [4] Patient-Reported Outcomes in Patients with Type 2 Diabetes Treated with Tirzepatide or Insulin Degludec (SURPASS-3)
    Yu, M.
    Bray, R.
    Brown, K.
    Lando, L. Fernandez
    Rodriguez, A.
    Boye, K.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [5] Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
    Battelino, Tadej
    Bergenstal, Richard M.
    Rodriguez, Angel
    Fernandez Lando, Laura
    Bray, Ross
    Tong, Zhentao
    Brown, Katelyn
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (06): : 407 - 417
  • [6] The Effect of Insulin Degludec vs. Insulin Glargine U100 on Continuous Glucose Monitoring (CGM) Recorded Glycemic Metrics in People with Type 1 Diabetes and Recurrent Nocturnal Severe Hypoglycemia
    Brosen, Julie M.
    Agesen, Rikke
    Alibegovic, Amra Ciric
    Andersen, Henrik U.
    Gustenhoff, Peter
    Hansen, Troels K.
    Hedetoft, Christoffer
    Stolberg, Charlotte R.
    Juhl, Claus B.
    Lerche, Susanne
    Norgaard, Kirsten
    Tarnow, Lise
    Thorsteinsson, Birger
    Pedersen-Bjergaard, Ulrik
    DIABETES, 2022, 71
  • [7] Tirzepatide reduces muscle fat infiltration relative to insulin deglucec in people with type 2 diabetes (SURPASS-3 MRI)
    Sattar, N.
    Linge, J.
    Neeland, I. J.
    Leinhard, O. Dahlqvist
    Lando, L. Fernandez
    Bray, R.
    Rodriguez, A.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S3 - S4
  • [8] Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in patients with type 2 diabetes (SURPASS-3 MRI)
    Gastaldelli, A.
    Cusi, K.
    Lando, L. Fernandez
    Bray, R.
    Brouwers, B.
    Rodriguez, A.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 219 - 220
  • [9] EFFECT OF TIRZEPATIDE VERSUS INSULIN DEGLUDEC ON LIVER FAT CONTENT AND ABDOMINAL ADIPOSE TISSUE IN PATIENTS WITH TYPE 2 DIABETES (SURPASS-3 MRI)
    Gastaldelli, A.
    Cusi, K.
    Lando, L. Fernandez
    Bray, R.
    Brouwers, B.
    Rodriguez, A.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A37 - A37
  • [10] Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3)
    Ludvik, Bernhard
    Giorgino, Francesco
    Jodar, Esteban
    Frias, Juan Pablo
    Lando, Laura Fernandez
    Brown, Katelyn
    Bray, Ross
    Rodriguez, Angel
    DIABETES, 2021, 70
12345